×
About 11,230 results

A Bigger Red Flag for CAR-T's Toll on the Heart, Lungs
https://www.medpagetoday.com/hematologyoncology/hematology/95248

Oct 25th, 2021 - Stronger signals of cardiovascular and pulmonary risk emerged in the largest postmarketing study of chimeric antigen receptor (CAR) T-cell therapy to date. In the FDA Adverse Event Reporting System (FAERS), the 2,657 patient reports for axicabtagene-ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) were associated with significant overreporting of: Compared with tisagenlecleucel, axicabtagen...

Myeloma Drug Pulled From Market Just Months After Approval
https://www.medpagetoday.com/hematologyoncology/myeloma/95223

Oct 22nd, 2021 - Just months after FDA granted accelerated approval of its myeloma drug, Oncopeptides has pulled melphalan flufenamide (melflufen, Pepaxto) from the market. The decision followed an FDA hold on clinical trials of the drug after data from a confirmatory trial showed an increased mortality risk in patients treated with melflufen. The phase III OCEAN study compared melflufen plus dexamethasone and ...

Arterial Chemo Tops Chemoembolization for Large Liver Tumors
https://www.medpagetoday.com/hematologyoncology/othercancers/95209

Oct 22nd, 2021 - Patients with unresectable large-volume liver cancer lived significantly longer when treated with hepatic-artery infusion chemotherapy (HAIC) than with transarterial chemoembolization (TACE), a randomized trial from China showed. Median overall survival (OS) increased from 16.1 months with TACE to 23.1 months with FOLFOX (leucovorin, fluorouracil, and oxaliplatin)-HAIC. Progression-free surviva...

Cabozantinib Shows Activity Against RCC Brain Metastases
https://www.medpagetoday.com/hematologyoncology/renalcellcarcinoma/95201

Oct 22nd, 2021 - The tyrosine kinase inhibitor (TKI) cabozantinib (Cabometyx) showed promising activity against brain metastases from renal cell carcinoma (RCC), researchers reported. In a retrospective cohort study of 88 patients with RCC brain metastases, the intracranial response rate with cabozantinib was 55% (95% CI 36-73%) in those with progressing brain metastases without concomitant brain-directed local...

A Silver Lining in Cancer; Dedicated Care for DCIS; New Vaccination Initiative
https://www.medpagetoday.com/hematologyoncology/othercancers/95184

Oct 21st, 2021 - A patient with breast cancer discovers the silver lining in her diagnosis and treatment. (ASCO Connection) Innovent Biologics announced that the PD-1 inhibitor sintilimab plus bevacizumab biosimilar (Byvasda) significantly improved progression-free survival in advanced EGFR-positive non-small cell lung cancer that progressed on prior EGFR-inhibitor therapy. By means of a complete response lette...

Rare Aggressive Bladder Cancer Treated Successfully in Elderly Man
https://www.medpagetoday.com/hematologyoncology/othercancers/95172

Oct 21st, 2021 - A 71-year-old man presented to hospital in November 2014 upon referral after reporting pain and evidence of blood on urination. Imaging and cystoscopy assessments identified a vegetative lesion of the bladder wall. The patient reported being a heavy smoker for the past 30 years. His medical history over the past 3 decades included high blood pressure, elevated cholesterol, and psoriasis. His su...

Analysis Confirms Benefits of CDK4/6 Inhibition in Early Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/95163

Oct 20th, 2021 - Adding a CDK4/6 inhibitor to adjuvant endocrine therapy significantly improved invasive disease-free survival (IDFS) and decreased the risk of distant relapse in early hormone receptor (HR)-positive/HER2-negative breast cancer, according to updated results from a randomized trial. The addition of abemaciclib (Verzenio) was associated with an IDFS hazard of 0.696 (95% CI 0.588-0.823, P<0.0001) a...

IDH2 Inhibitor Combo Boosts Response Rates in Newly Diagnosed AML
https://www.medpagetoday.com/hematologyoncology/leukemia/95149

Oct 20th, 2021 - Adding an isocitrate dehydrogenase 2 (IDH2) inhibitor to azacitidine significantly improved response rates for patients with newly diagnosed IDH2-mutant acute myeloid leukemia (AML) who were ineligible for intensive chemotherapy, a randomized phase Ib/II trial found. Of 68 patients who received enasidenib (Idhifa) plus azacitidine, the overall response rate (ORR) was 74% compared with 36% in th...

Liposomal Irinotecan Combo Boosts Survival in Biliary Tract Cancer
https://www.medpagetoday.com/hematologyoncology/othercancers/95112

Oct 18th, 2021 - Adding liposomal irinotecan to fluorouracil and leucovorin significantly improved progression-free survival (PFS) in patients with advanced biliary tract cancer after progression on gemcitabine plus cisplatin, according to results from a randomized phase IIb trial. At a median follow-up of 11.8 months, the liposomal irinotecan combination resulted in a blinded independent central review (BICR)-...

Right-Sided CRC Metastases Call for 'More Aggressive' Approach
https://www.medpagetoday.com/hematologyoncology/coloncancer/95103

Oct 18th, 2021 - Colorectal cancer (CRC) metastases from right-sided primary tumors and CRC liver metastases had higher rates of local failure following stereotactic ablative radiotherapy (SABR), a single-institution retrospective study found. Among 130 patients with oligometastatic CRC, lesions stemming from right-sided CRCs were more than twice as likely to recur locally following SABR, as compared with left-...

First Adjuvant Immunotherapy OK'd in Non-Small Cell Lung Cancer
https://www.medpagetoday.com/hematologyoncology/lungcancer/95079

Oct 15th, 2021 - The FDA approved the PD-L1 inhibitor atezolizumab (Tecentriq) as adjuvant treatment following surgery and platinum-based chemotherapy for stage II-IIIa non-small cell lung cancer (NSCLC) that expresses PD-L1. The new approval makes atezolizumab the first immunotherapy to get an adjuvant indication for NSCLC, drugmaker Roche announced. "Too many patients with early-stage lung cancer experience d...

Daratumumab-Based Combo Boosts Multiple Myeloma Survival
https://www.medpagetoday.com/hematologyoncology/myeloma/95074

Oct 15th, 2021 - Adding daratumumab (Darzalex) to lenalidomide (Revlimid) and dexamethasone -- the DRd regimen -- boosted survival in newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplant, an updated analysis of the MAIA trial showed. At a median follow-up of 56.2 months, treatment with DRd demonstrated a significant 32% reduction in the risk of death from any cause versus len...

Abiraterone Active in Androgen Receptor-Positive Salivary Tumors
https://www.medpagetoday.com/hematologyoncology/othercancers/95051

Oct 14th, 2021 - A majority of patients with previously treated androgen receptor (AR)-expressing salivary gland cancer (SGC) achieved disease control with abiraterone (Zytiga) plus a luteinizing hormone-releasing hormone (LHRH) agonist, a small phase II trial showed. Five of 24 patients had partial responses, and 10 others had stable disease for a disease control rate (DCR) of 62.5%. The cohort had a median pr...

Support for Rare Cancers; Medical Record Anguish; Walgreens Vows Tobacco Scrutiny
https://www.medpagetoday.com/hematologyoncology/othercancers/95052

Oct 14th, 2021 - The FDA awarded 11 grants to support research in rare diseases, including cancers. A grieving mother shares her frustration and anguish over being denied access to her daughter's medical records after the 3-year-old died of a brain tumor. (Journal of Clinical Oncology) Merck announced FDA approval of pembrolizumab (Keytruda) in combination with chemotherapy, with or without bevacizumab, for the...

Newly Approved EGFR Drug Yields Meaningful Benefit in Rare NSCLCs
https://www.medpagetoday.com/hematologyoncology/lungcancer/95041

Oct 14th, 2021 - Treatment with mobocertinib (Exkivity) led to clinically meaningful benefits with a manageable safety profile in patients with previously treated EGFR exon 20 insertion mutation-positive metastatic non-small cell lung cancer (NSCLC), researchers found. The primary endpoint of confirmed objective response rate (ORR) by independent review committee (IRC) was 28% with the oral tyrosine kinase inhi...

First CDK4/6 Inhibitor OK'd for Early, High-Risk Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/95015

Oct 13th, 2021 - The FDA approved the CDK4/6 inhibitor abemaciclib (Verzenio), in combination with standard adjuvant endocrine therapy, for certain patients with early breast cancer who are at high risk of recurrence, Eli Lilly announced. Indicated for patients who are node-positive and have hormone receptor-positive/HER2-negative disease, eligibility for the combination further requires a score of ≥20% on the ...

Almost Half of Breast Cancer Patients Use Cannabis, Survey Finds
https://www.medpagetoday.com/hematologyoncology/breastcancer/94995

Oct 12th, 2021 - More than four in 10 breast cancer patients use cannabis, most often to relieve side effects associated with treatment, such as pain, anxiety, nausea, and insomnia, according to a survey study. Of the Coala-T-Cannabis survey respondents who reported using cannabis, 75% said it was extremely helpful or very helpful in alleviating symptoms, reported Marisa Weiss, MD, of Breastcancer.org and Lanke...

Ibrutinib-Rituximab Wins Out in Waldenstrom's Macroglobulinemia
https://www.medpagetoday.com/hematologyoncology/lymphoma/94959

Oct 11th, 2021 - The combination of the Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (Imbruvica) and rituximab was superior to rituximab alone across all clinical outcomes for patients with Waldenstrom's macroglobulinemia, a rare B-cell lymphoma, according to the final analysis of the randomized phase III iNNOVATE study. Over a median follow-up of 50 months, median progression-free survival (PFS) was not ...

Patients and Tumor Genomics; Big Jump in Esophageal Cancer; Cervical Cell Lawsuit
https://www.medpagetoday.com/hematologyoncology/othercancers/94908

Oct 7th, 2021 - Patients at community oncology centers had high expectations for genomic tumor testing in association with limited understanding of how the tests work. (JCO Precision Oncology) A doctor who spent a year hoping to make a difference in the lives of indigenous residents of northern Canada instead found just the opposite. (JAMA) Florida Gov. Ron DeSantis's wife, Casey, has breast cancer. (CNN) The ...

Standard of Care Hard to Beat in HER2-Negative Breast Cancer
https://www.medpagetoday.com/hematologyoncology/breastcancer/94900

Oct 7th, 2021 - Pairing the CDK4/6 inhibitor palbociclib (Ibrance) with fulvestrant as first-line treatment for advanced, hormone receptor-positive/HER2-negative breast cancer did not improve survival compared with standard treatment, the phase II PARSIFAL trial found. Over a median follow-up of 32 months, the primary endpoint of median investigator-assessed progression-free survival (PFS) was 27.9 months in t...